Neil Pressman Discusses Healthcare Management Consulting

The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.

A new FDA-approved blood test for Alzheimer disease could transform diagnosis and treatment accessibility, according to this conversation with Howard Fillit, MD, and Anthony “Nino” Sireci, MD, MSc.

Underdosing, poor spleen response, and transfusion dependence drive inferior survival outcomes in intermediate-1 myelofibrosis.

In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.

By 2040, advanced metabolic dysfunction–associated steatohepatitis (MASH) is projected to rise by at least 20% in the 9 countries assessed.

John Byrnes of Banner|Aetna emphasizes collaboration and data-driven strategies to enhance care quality, access, and affordability in health care.